Document Details

Document Type : Article In Journal 
Document Title :
Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma
Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma
 
Document Language : English 
Abstract : BACKGROUND: Screening medullary thyroid carcinomas (MTCs) for rearranged during transfection (RET) mutations becomes increasingly important for clinical assessment of the disease. The role of mutations in other genes including RAS (i.e. HRAS, KRAS, and NRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-akt murine thymoma viral oncogene homolog 1 (AKT1), and CTNNB1 (β-catenin) is unknown or not fully explored yet for this disease. MATERIALS AND METHODS: Formalin-fixed and paraffin-embedded (FFPE) material was the primary source for screening 13 sporadic and inherited MTCs and matched non-tumor specimens. Multiplex PCR was included in the PCR protocol. Sequence analysis encompassed mutational hotspot regions in RET exons 5, 8, 10, 11, and 13 to 16; HRAS exons 1 and 2; KRAS exons 1 and 2; NRAS exons 1 and 2; BRAF exon 15; AKT1 exon 2, and CTNNB1 exon 3. RESULTS: We identified RET mutations in seven of 13 MTCs: five RET-positive cases revealed a mutation in exon 16 (M918T) and two a mutation in exon 10 (C618S and C620S). In four of the RET-positive cases, the mutation was inherited, out of which three were reportedly associated with a multiple endocrine neoplasia type 2 (MEN2) syndrome, i.e. MEN2A (C618S), MEN2A/familial MTC (FMTC) (C620S), and MEN2B (M918T). These cases reflect the known MEN2 genotype-phenotype correlation. Three of the five stage IVc MTCs were inherited RET-positive cases. Mutational screening in HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 disclosed one sporadic RET-negative MTC (stage III) with mutation in HRAS codon 13 (G13R). CONCLUSION: Our study supports the clinical relevance of screening MTC patients for RET mutations. The role of RAS mutations, in particular HRAS mutations, in sporadic RET-negative MTC has not been fully explored yet. Mutations in BRAF, AKT1, and CTNNB1 are likely not to play a role in MTC. 
ISSN : 0250-7005 
Journal Name : Anticancer research 
Volume : 31 
Issue Number : 12 
Publishing Year : 1432 AH
2011 AD
 
Article Type : Article 
Added Date : Tuesday, March 8, 2016 

Researchers

Researcher Name (Arabic)Researcher Name (English)Researcher TypeDr GradeEmail
Hans-Juergen SchultenSchulten, Hans-Juergen InvestigatorDoctoratehschulten@kau.edu.sa
Jaudah Al-MaghrabiAl-Maghrabi, Jaudah ResearcherDoctorate 
Khalid Al-GhamdiAl-Ghamdi, Khalid Researcher  
Sherine SalamaSalama, Sherine Researcher  
Saad Al-MuhayawiAl-Muhayawi, Saad Researcher  
Adeel ChaudharyChaudhary, Adeel ResearcherDoctorate 
Osman HamourHamour, Osman Researcher  
Adel AbuzenadahAbuzenadah, Adel ResearcherDoctorate 
Mamdooh GariGari, Mamdooh ResearcherDoctorate 
Mohammed Al-QahtaniAl-Qahtani, Mohammed ResearcherDoctorate 

Files

File NameTypeDescription
 38410.pdf pdf 

Back To Researches Page